XORTX Therapeutics Initiates Reverse Stock Split to Maintain Nasdaq Listing

In a strategic move to preserve its position on the Nasdaq exchange, XORTX Therapeutics is implementing a reverse stock split. The biopharmaceutical company is consolidating its shares at a ratio of 5-to-1, a direct response to sustained share price pressure and the imminent threat of delisting.

A Strategic Consolidation to Meet Listing Rules

The primary objective of this corporate action is to elevate the trading price of XORTX shares above the critical $1.00 threshold. Nasdaq listing regulations mandate that a company’s stock must maintain a minimum bid price of $1.00 for ten consecutive trading days. XORTX faces a compliance deadline of April 13, 2026.

Shareholders provided the necessary approval for this measure during a meeting held on March 24. While the number of outstanding shares will be significantly reduced, the underlying economic value of each shareholder’s investment is intended to remain unchanged, barring any negative market reaction to the restructuring itself.

Key Details and Timeline of the Share Consolidation

The technical process of the reverse split is scheduled to commence on Friday, March 27, 2026, pending final confirmation from the TSX Venture Exchange. The company has proceeded based on the authority granted by its shareholder vote.

Should investors sell immediately? Or is it worth buying XORTX Therapeutics?

Consolidation Summary:
– Ratio: 5 old shares for 1 new share
– Approximate Outstanding Shares (Pre-Consolidation): 6,962,218
– Approximate Outstanding Shares (Post-Consolidation): 1,392,443
– Effective Date: March 27, 2026
– Nasdaq Compliance Deadline: April 13, 2026

As part of this process, the consolidated shares will be assigned a new CUSIP identifier for clear distinction in trading. Fractional shares resulting from the consolidation will be handled according to standard procedures, typically involving cash settlement or rounding.

Following the effective date, market attention will shift to the stock’s performance over the subsequent two-week period. The crucial test will be whether the adjusted share price can consistently trade above the $1.00 level, thereby allowing the company to satisfy the Nasdaq’s minimum bid price requirement ahead of the April 13 deadline.